Turkey Pharmaceuticals Market Competition, Forecast & Opportunities, 2030: High-Value Segments and Digital Transformation Drive Growth
The Turkey Pharmaceuticals Market offers opportunities in expanding generic drug capabilities and digital healthcare innovations like e-pharmacies. An aging population is driving demand, while regulatory challenges present constraints. Multinational involvement in high-value segments enhances growth potential.
Turkish Pharmaceuticals Market
Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Turkey Pharmaceuticals Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to ResearchAndMarkets.com's offering.
The Turkey Pharmaceuticals Market was valued at USD 2.10 Billion in 2024, and is expected to reach USD 2.70 Billion by 2030, rising at a CAGR of 4.25%
The market has shown steady growth driven by rising healthcare expenditure, demographic shifts, and evolving health policy frameworks. As one of the leading pharmaceutical markets in the MENA region, Turkey plays a key role in the global pharmaceutical landscape. The presence of multinational corporations in specialized areas such as oncology, immunology, and rare diseases has strengthened the high-value segment.
Concurrently, domestic manufacturers have expanded their capabilities in generic drugs, biosimilars, and API production, increasing competitiveness and improving market access. While this enhances local capacity and self-sufficiency, it also presents challenges related to pricing and regulatory complexities.
Key Market Drivers: Growing Healthcare Needs and Aging Population:
The rising healthcare demands coupled with Turkey's aging population are central to the market's expansion. Healthcare spending accounts for around 4.5% of the country's GDP, with per capita expenditure increasing significantly since the implementation of the Healthcare Transformation Program in 2002.
According to OECD data, spending per capita has reached USD 857, reflecting a continued investment in improving healthcare access and quality. An aging population is leading to a growing prevalence of non-communicable diseases such as cancer, diabetes, cardiovascular conditions, arthritis, and Alzheimer's. This epidemiological transition is increasing the need for long-term treatments and pharmaceuticals, significantly influencing drug consumption trends and creating long-term opportunities for the industry.
Key Market Challenges: Pricing and Reimbursement Constraints
A major constraint in the Turkish pharmaceutical market is the government's strict pricing and reimbursement mechanisms aimed at cost containment. The use of an international reference pricing system: based on the lowest drug prices in selected European countries: often results in suppressed pricing levels.
Additionally, the long-standing artificial exchange rate applied to pharmaceutical imports further reduces the profitability of international companies operating in Turkey. These pricing models, coupled with prolonged reimbursement approval timelines, limit the financial viability of launching new and innovative drugs. Such policies have the potential to deter foreign investment, limit product variety, and reduce patient access to cutting-edge therapies, ultimately affecting market innovation and growth.
Key Market Trends: Digitalization of Healthcare and E-Pharmacy Expansion
The Turkish pharmaceutical industry is increasingly embracing digital transformation through the adoption of telemedicine, electronic prescriptions, health informatics, and online pharmacies. These developments are streamlining healthcare delivery, improving compliance, and opening up new revenue opportunities.
The integration of e-prescription systems has enhanced drug traceability and inventory oversight for pharmacies. With the rising popularity of online purchasing: especially among urban consumers: pharmaceutical firms are expanding their e-commerce capabilities. Additionally, the normalization of digital consultations and remote healthcare services post-pandemic has led to an uptick in outpatient pharmaceutical sales, signaling a fundamental shift in how medicines are accessed and consumed.
Key Attributes:
Report Attribute
Details
No. of Pages
85
Forecast Period
2024 - 2030
Estimated Market Value (USD) in 2024
$2.1 Billion
Forecasted Market Value (USD) by 2030
$2.7 Billion
Compound Annual Growth Rate
4.2%
Regions Covered
Turkey
Report ScopeKey Market Players: Amgen Inc.
Bilim Ilac Sanayii ve Ticaret Anonim Sirketi
Bristol-Myers Squibb Company
EastPharma Ltd
Ferring Ilac Sanayi ve Ticaret Ltd Sti (Ferring Global)
Gensenta Ilac Sanayi ve Ticaret A.S.
GlaxoSmithKline Turkey
ITALFARMACO S.p.A.
Menarini Turkiye (Menarini Group)
Merck & Co.
MS Pharma
Novartis Turkey
Pfizer Turkey
Takeda Pharmaceutical Company
Turkey Pharmaceuticals Market, By Drug Type:
Generic
Branded Drugs
Turkey Pharmaceuticals Market, By Product Type:
Over-The-Counter Drugs
Prescription Drugs
Turkey Pharmaceuticals Market, By Application:
Cardiovascular
Oncology
Metabolic Disorder
Musculoskeletal
Anti-infective
Others
Turkey Pharmaceuticals Market, By Distribution Channel:
Retail Pharmacy
Hospital Pharmacy
E-Pharmacy
Turkey Pharmaceuticals Market, By Region:
Marmara Region
Central Anatolia
Eastern Anatolia Region
South-Eastern Anatolia Region
Aegean Region
Mediterranean Region
Black Sea Region
For more information about this report visit https://www.researchandmarkets.com/r/kuc4yv
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Turkish Pharmaceuticals Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Trading Day: Market inflection points abound
By Jamie McGeever ORLANDO, Florida (Reuters) - TRADING DAY Making sense of the forces driving global markets By Jamie McGeever, Markets Columnist Stocks and the dollar rose solidly on Tuesday even though markets lacked a central, driving force - signs of weakening economic activity, cooling labor markets and disinflation are all reasons for caution, but risk appetite continues to be fueled by hopes that U.S.-China trade tensions will soon ease. In my column today I look at why foreign investors' exposure to U.S. assetsmay not be as high as feared. If it's not, the potential downside for Wall Street and Treasuries from diversification may be less severe. More on that below, but first, a roundup of the main market moves. If you have more time to read, here are a few articles I recommend to help you make sense of what happened in markets today. 1. Markets anxious as 'new cold war' turns hot: Mike Dolan 2. FX options market positioned for further dollar weakness 3. OECD lowers global outlook as Trump trade war hits 4. Japan to promote domestic ownership of JGBs, policydraft shows 5. G7 debt is now a pressure point for anxious markets Today's Key Market Moves * The S&P 500 hits a three-month high, rising 0.6% on theday, and the Nasdaq hits its highest level since February aftera 0.7% rise. * The dollar rebounds 0.6%, but only after plumbing afresh six-week low. It gains most vs yen, Swiss franc andSwedish krona, up 1% against all three. * One of the quietest days in weeks for the U.S. bondmarket, with the 10- and 30-year yields recording their smallestmoves since May 9. Each barely moves a basis point. * Oil rises for a second day, with Brent and WTI futuresup around 2%, on geopolitical tensions and supply worries. * Gold slips almost 1% but earlier in the day hits$3,392/oz, its highest since May 8. Market inflection points abound Evidence is mounting that global economic activity is slowing, but this is failing to move the dial much for markets. Investors know growth is slowing and that the second half of the year will be challenging, so that's already 'in the price'. Hopes of a de-escalation in the trade standoff between the U.S. and China, and for bilateral deals between the U.S. and other key trading partners soon are supporting risk assets. The S&P 500 hit a three-month high on Tuesday, while the Nasdaq and MSCI World index climbed to levels last visited in February. It is the strength on Wall Street, most latterly tech, that is lifting global stocks as benchmark Asian and European indices are flatlining. On the whole, policymakers continue to stress that they are data-dependent and will move on rates carefully and calmly. That was the message from various Fed officials this week and Bank of England Governor Andrew Bailey on Tuesday. It's a slightly different - although no less challenging - situation in mainland Europe, where figures on Tuesday showed disinflationary forces are driving consumer prices as much as anything else. Euro zone inflation dipped below the European Central Bank's 2% target in May, cementing expectations rates will be cut this week and later this year. Meanwhile, Switzerland experienced outright year-on-year deflation for the first time in four years, raising the possibility that the Swiss National Bank may soon reintroduce negative interest rates. Canada's central bank is expected to hold interest rates at 2.75% on Wednesday for a second meeting. Growth and inflation have been surprisingly sticky this year, and rates have been slashed by 225 basis points since last June. As UBS analysts note, markets are generally at an inflection point, waiting for the catalyst that will break them out of the narrow ranges that have broadly held since the U.S. and China announced a temporary reduction on tariffs on May 12. Even Wall Street and the dollar - one creeping higher, the other drifting lower - are awaiting a trigger for a proper breakout. Could the telephone call between U.S. President Donald Trump and Chinese leader Xi Jinping expected later this week be it? Foreign exposure to U.S. assets may be lower than feared It is widely believed that investors around the world have a disproportionately high exposure to U.S. assets, particularly stocks, an imbalance that could roil U.S. markets if corrected. But what if these fears are overblown? Several eye-popping statistics suggest that America's weight in world financial markets is even greater than its outsized economic might. Most strikingly, the U.S. net international investment position (NIIP), or foreign investors' holdings of U.S. assets less U.S. investors' holdings of overseas assets, at the end of 2024 was $26 trillion. That's nearly 24% of global GDP, up from 16% only two years earlier, a surge driven by foreigners' insatiable appetite for U.S. equities, mainly "Big Tech". Demand was so hot that, by some measures, the value of U.S.-listed stocks at the turn of the year represented 74% of total global market cap. That share was 60% six years ago, and less than half in 2011. But the attractiveness of dollar-denominated assets is now being questioned, as the often erratic policies of U.S. President Donald Trump have upset longstanding economic and geopolitical norms, making governments and investors question whether Washington is still a reliable partner on the global stage. The concern is that this eroding confidence triggers a reversal of the massive flows into Wall Street seen in recent years that has damaging spillover effects. Such a correction may not require outright selling. Given the scale of the flows involved, just less buying among foreign investors could be enough to cast a shadow over the world's most important stock market. And the running assumption is foreign investors don't have the capacity or willingness to increase their exposure to U.S. assets, creating a significant long-term downside risk for Wall Street, Treasuries and the dollar. "A structural shift is underway: the slow erosion of US economic dominance," analysts at Deutsche Bank wrote on Monday. SKEPTICAL But looked at another way, foreign exposure to U.S. assets may not be as high as initially meets the eye. That's the view of analysts at JP Morgan, who measure portfolio investment in U.S. bonds and equities as a share of countries' total household sector financial assets. They use a broad definition for a country's "household" sector, covering investments by institutions like insurance companies and pension funds that are ultimately made on behalf of households. Using a broad range of data, from central banks, U.S. Treasury and OECD household financial asset flows, they measure the ratio of U.S. equity and bond holdings relative to household financial assets in each country. They find that "relative to the total financial assets of households in the rest of the world, the allocations to U.S. assets typically stand at around 10-20%." As a result, they are "skeptical of the idea that foreign investors hold too much of U.S. assets." Given that U.S. equities account for more than 70% of the MSCI global market cap and dollar-denominated bonds represent around 50% of global bond indices, according to JP Morgan estimates, the 10-20% exposure of foreign investors to U.S. assets does appear surprisingly low. And the 10-20% figure would be even lower were it not for the outsized U.S. equity holdings at the Swiss National Bank and Norway's sovereign wealth fund. On the bond side, foreigners' footprint in the U.S. Treasury market is shrinking. Data shows that they owned 31% of the $28.55 trillion outstanding Treasury debt at the end of last year. That share has been declining steadily since the Global Financial Crisis. In 2008, the figure was approaching 60%. Overseas investors' share of the T-bill market has shrunk even more. In December, it was under 20%, near its lowest level on record and sharply down from 50% a decade before. Nikolaos Panigirtzoglou and his team at JP Morgan aren't arguing investors will or should ramp up their purchases of U.S. assets. And in cases where allocations are high - such as the Taiwanese exposure to U.S. bonds or Canadians' holdings of U.S. stocks - diversification would hardly be a surprise. But there is "little indication" of broad-based selling of U.S. assets by foreign investors so far this year, they note. And if that selling does materialize, it may be far lighter than many expect. What could move markets tomorrow? * Australia GDP (Q1) * South Korea inflation (May) * South Korea GDP (Q1, revised) * UK services PMI (May) * Canada interest rate decision * U.S. services ISM (May) * U.S. ADP employment (May) * Federal Reserve releases Beige Book Opinions expressed are those of the author. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias. (By Jamie McGeever; Editing by Nia Williams) Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
38 minutes ago
- Yahoo
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's chief executive officer, will participate in a fireside at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 10:00 a.m. ET. The live and archived webcast of the panel will be accessible from the company's website at About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency. For more information on Ultragenyx, please visit the company's website at: Contacts – Ultragenyx Pharmaceutical, Higa ir@
Yahoo
38 minutes ago
- Yahoo
Sprott Focus Trust, Inc. (Nasdaq-FUND) Declares Second Quarter Common Stock Distribution of $0.1280 Per Share
TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Sprott Focus Trust, Inc. (Nasdaq-FUND) (the 'Fund' or 'FUND') has declared a quarterly distribution of $0.1280 per share on its Common Stock. The distribution, optionally payable in additional shares of Common Stock or in cash by specific stockholder election, is to be paid on June 30, 2025 to stockholders of record at the close of business on June 13, 2025 (ex-dividend on June 13, 2025). The price of shares issued for reinvestment will be determined on June 23, 2025. The Fund currently has adopted a Distribution Policy of paying quarterly distributions on its Common Stock. Distributions are being made at the annual rate of 6% of the rolling average of the prior four calendar quarter-end net asset values ('NAVs'), with the fourth quarter distribution being the greater of 1.50% of the rolling average or the minimum distribution required by IRS regulations. The policy, including the annual rate, is subject to change at the discretion of the Fund's Board of Directors. The Fund's estimated sources of the distribution to be paid on June 30, 2025 and for 2025 year-to-date are as follows: Estimated Allocations as of May 31, 2025 Distribution Per Share Net Investment Income Net Realized Short-Term Gains Net Realized Long-Term Gains Return of Capital FUND $ 0.1280 $ 0.0491 (38.36%) $ 0.0021 (1.64%) $ 0.0768 (60.00%) $ 0.0000 (0.00%) Estimated Allocations for 2025 through May 31, 2025 Distribution Per Share Net Investment Income Net Realized Short-Term Gains Net Realized Long-Term Gains Return of Capital FUND $ 0.2585 $ 0.0881 (34.08%) $ 0.0021 (0.81%) $ 0.1464 (56.65%) $ 0.0219 (8.46%) You should not draw any conclusions about the Fund's investment performance from the amount of the current distribution or from the terms of the Fund's Distribution Policy. The amounts and sources of distributions reported herein are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes. Fund Performance and Distribution Rate Information Average Annual Total Return (in relation to NAV for the 5-year period ending on 05/31/2025)1 Annualized Current Distribution Rate (expressed as a percentage of NAV as of 05/31/2025)2 Cumulative total return (in relation to NAV for the fiscal year through 05/31/2025)3 Cumulative fiscal year Distribution Rate (as a percentage of NAV as of 05/31/2025)4 FUND 11.85% 1.58% -1.38% 3.19% 1 Average Annual Total Return in relation to NAV represents the compound average of the Annual NAV Total Returns of the Fund for the five year period ended May 31, 2025. Annual NAV Total Return is the percentage change in the Fund's NAV over a year, assuming reinvestment of distributions paid. 2 The Annualized Current Distribution Rate is the current fiscal period's distribution rate annualized as a percentage of the Fund's NAV as of May 31, 2025. 3 Cumulative Total Return is the percentage change in the Fund's NAV from December 31, 2024 to May 31, 2025, assuming reinvestment of distributions paid. 4 The Cumulative Fiscal Year Distribution Rate is the dollar value of distributions for the fiscal year period (January 1, 2025 to May 31, 2025), as a percentage of the Fund's NAV as of May 31, 2025. About Sprott Focus Trust, Inc. Sprott Focus Trust, Inc. is a closed-end diversified investment management company whose shares of Common Stock are listed and traded on the Nasdaq Global Select Market. The Fund's investment goal is long-term capital growth, which it seeks by normally investing at least 65% of its assets in equity securities. For further information on the Fund, please visit our web site at: An investor should consider investment objectives, risks, charges and expenses carefully before investing. The Fund is a closed-end fund and closed-end funds do not continuously issue shares for sale as open-end mutual funds do. The Fund trades in the secondary market. Investors wishing to buy or sell shares need to place orders through an intermediary or broker. Suite 230 | 320 Post Road | Darien, Connecticut | USA 06820 | (203) 636-0977 | Contact: Glen Williams (416) 943-4394Sign in to access your portfolio
